SAB Biotherapeutics Ownership 2024 | Who Owns SAB Biotherapeutics Now?
Institutional Ownership
5.11%
Insider Ownership
19.15%
Retail Ownership
75.74%
Institutional Holders
37.00
SAB Biotherapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
JPMORGAN CHASE & CO | - | - | - | -951 | -100.00% | - | Mar 31, 2024 |
BANK OF AMERICA CORP /DE/ | - | - | - | -54 | -100.00% | - | Mar 31, 2024 |
WELLS FARGO & COMPANY/MN | - | - | - | -294 | -100.00% | - | Mar 31, 2024 |
NORTHERN TRUST CORP | - | - | - | -44,476 | -100.00% | - | Mar 31, 2024 |
STATE STREET CORP | - | - | - | -81,241 | -100.00% | - | Mar 31, 2024 |
VANGUARD GROUP INC | - | - | - | -996,132 | -100.00% | - | Mar 31, 2024 |
FMR LLC | - | - | - | -343 | -100.00% | - | Mar 31, 2024 |
1ST SOURCE BANK | - | - | - | -10,000 | -100.00% | - | Mar 31, 2024 |
FIRST MANHATTAN CO. LLC. | - | - | - | -277,777 | -100.00% | - | Mar 31, 2024 |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | - | - | - | -16,238 | -100.00% | - | Mar 31, 2024 |
MORGAN STANLEY | - | - | - | -11,506 | -100.00% | - | Mar 31, 2024 |
RENAISSANCE TECHNOLOGIES LLC | - | - | - | -63,100 | -100.00% | - | Mar 31, 2024 |
PEAPACK GLADSTONE FINANCIAL CORP | - | - | - | -52,296 | -100.00% | - | Mar 31, 2024 |
BVF INC/IL | - | - | - | -9,178,282 | -100.00% | - | Mar 31, 2024 |
SILVER OAK SECURITIES, INCORPORATED | - | - | - | -51,891 | -100.00% | - | Mar 31, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -356,364 | -100.00% | - | Mar 31, 2024 |
BLACKROCK INC. | - | - | - | -52,643 | -100.00% | - | Mar 31, 2024 |
MARINER, LLC | - | - | - | -69,000 | -100.00% | - | Mar 31, 2024 |
CITADEL ADVISORS LLC | - | - | - | -16,719 | -100.00% | - | Mar 31, 2024 |
RTW INVESTMENTS, LP | - | - | - | -9,178,282 | -100.00% | - | Mar 31, 2024 |
SAB Biotherapeutics's largest institutional shareholder is JPMORGAN CHASE & CO, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
JPMORGAN CHASE & CO | - | - | - | -951 | -100.00% | - | Mar 31, 2024 |
BANK OF AMERICA CORP /DE/ | - | - | - | -54 | -100.00% | - | Mar 31, 2024 |
WELLS FARGO & COMPANY/MN | - | - | - | -294 | -100.00% | - | Mar 31, 2024 |
NORTHERN TRUST CORP | - | - | - | -44,476 | -100.00% | - | Mar 31, 2024 |
STATE STREET CORP | - | - | - | -81,241 | -100.00% | - | Mar 31, 2024 |
VANGUARD GROUP INC | - | - | - | -996,132 | -100.00% | - | Mar 31, 2024 |
FMR LLC | - | - | - | -343 | -100.00% | - | Mar 31, 2024 |
1ST SOURCE BANK | - | - | - | -10,000 | -100.00% | - | Mar 31, 2024 |
FIRST MANHATTAN CO. LLC. | - | - | - | -277,777 | -100.00% | - | Mar 31, 2024 |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | - | - | - | -16,238 | -100.00% | - | Mar 31, 2024 |
MORGAN STANLEY | - | - | - | -11,506 | -100.00% | - | Mar 31, 2024 |
RENAISSANCE TECHNOLOGIES LLC | - | - | - | -63,100 | -100.00% | - | Mar 31, 2024 |
PEAPACK GLADSTONE FINANCIAL CORP | - | - | - | -52,296 | -100.00% | - | Mar 31, 2024 |
BVF INC/IL | - | - | - | -9,178,282 | -100.00% | - | Mar 31, 2024 |
SILVER OAK SECURITIES, INCORPORATED | - | - | - | -51,891 | -100.00% | - | Mar 31, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -356,364 | -100.00% | - | Mar 31, 2024 |
BLACKROCK INC. | - | - | - | -52,643 | -100.00% | - | Mar 31, 2024 |
MARINER, LLC | - | - | - | -69,000 | -100.00% | - | Mar 31, 2024 |
CITADEL ADVISORS LLC | - | - | - | -16,719 | -100.00% | - | Mar 31, 2024 |
RTW INVESTMENTS, LP | - | - | - | -9,178,282 | -100.00% | - | Mar 31, 2024 |
The largest SAB Biotherapeutics shareholder by % of total assets is JPMORGAN CHASE & CO. The company owns 0.00 shares of SAB Biotherapeutics (SABS), representing 0.00% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
BANK OF AMERICA CORP /DE/ | - | - | - | -54 | -100.00% | - | Mar 31, 2024 |
QUBE RESEARCH & TECHNOLOGIES LTD | - | - | - | -69 | -100.00% | - | Mar 31, 2024 |
NEWEDGE ADVISORS, LLC | - | - | - | -145 | -100.00% | - | Mar 31, 2024 |
WELLS FARGO & COMPANY/MN | - | - | - | -294 | -100.00% | - | Mar 31, 2024 |
FMR LLC | - | - | - | -343 | -100.00% | - | Mar 31, 2024 |
UBS GROUP AG | - | - | - | -500 | -100.00% | - | Mar 31, 2024 |
JPMORGAN CHASE & CO | - | - | - | -951 | -100.00% | - | Mar 31, 2024 |
GS INVESTMENTS, INC. | - | - | - | -2,000 | -100.00% | - | Mar 31, 2024 |
LM ADVISORS LLC | - | - | - | -3,620 | -100.00% | - | Mar 31, 2024 |
SPECTRUM WEALTH COUNSEL, LLC | - | - | - | -5,030 | -100.00% | - | Mar 31, 2024 |
ELGETHUN CAPITAL MANAGEMENT | - | - | - | -5,435 | -100.00% | - | Mar 31, 2024 |
BAIRD FINANCIAL GROUP, INC. | - | - | - | -10,000 | -100.00% | - | Mar 31, 2024 |
1ST SOURCE BANK | - | - | - | -10,000 | -100.00% | - | Mar 31, 2024 |
MORGAN STANLEY | - | - | - | -11,506 | -100.00% | - | Mar 31, 2024 |
NADLER FINANCIAL GROUP, INC. | - | - | - | -13,750 | -100.00% | - | Mar 31, 2024 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -15,235 | -100.00% | - | Mar 31, 2024 |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | - | - | - | -16,238 | -100.00% | - | Mar 31, 2024 |
CITADEL ADVISORS LLC | - | - | - | -16,719 | -100.00% | - | Mar 31, 2024 |
NORTHERN TRUST CORP | - | - | - | -44,476 | -100.00% | - | Mar 31, 2024 |
ADVISOR GROUP HOLDINGS, INC. | - | - | - | -46,373 | -100.00% | - | Mar 31, 2024 |
As of Mar 31 2024, SAB Biotherapeutics's largest institutional buyer is BANK OF AMERICA CORP /DE/. The company purchased -54.00 stocks of SABS, valued at -.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
BVF INC/IL | - | - | - | -9,178,282 | -100.00% | - | Mar 31, 2024 |
RTW INVESTMENTS, LP | - | - | - | -9,178,282 | -100.00% | - | Mar 31, 2024 |
SESSA CAPITAL IM, L.P. | - | - | - | -4,584,571 | -100.00% | - | Mar 31, 2024 |
VANGUARD GROUP INC | - | - | - | -996,132 | -100.00% | - | Mar 31, 2024 |
FIRST PREMIER BANK | - | - | - | -807,535 | -100.00% | - | Mar 31, 2024 |
PATHSTONE HOLDINGS, LLC | - | - | - | -506,513 | -100.00% | - | Mar 31, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -356,364 | -100.00% | - | Mar 31, 2024 |
FIRST MANHATTAN CO. LLC. | - | - | - | -277,777 | -100.00% | - | Mar 31, 2024 |
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | - | - | - | -192,027 | -100.00% | - | Mar 31, 2024 |
KESTRA ADVISORY SERVICES, LLC | - | - | - | -88,000 | -100.00% | - | Mar 31, 2024 |
STATE STREET CORP | - | - | - | -81,241 | -100.00% | - | Mar 31, 2024 |
MARINER, LLC | - | - | - | -69,000 | -100.00% | - | Mar 31, 2024 |
RENAISSANCE TECHNOLOGIES LLC | - | - | - | -63,100 | -100.00% | - | Mar 31, 2024 |
BLACKROCK INC. | - | - | - | -52,643 | -100.00% | - | Mar 31, 2024 |
PEAPACK GLADSTONE FINANCIAL CORP | - | - | - | -52,296 | -100.00% | - | Mar 31, 2024 |
SILVER OAK SECURITIES, INCORPORATED | - | - | - | -51,891 | -100.00% | - | Mar 31, 2024 |
CREATIVE PLANNING | - | - | - | -47,518 | -100.00% | - | Mar 31, 2024 |
ADVISOR GROUP HOLDINGS, INC. | - | - | - | -46,373 | -100.00% | - | Mar 31, 2024 |
NORTHERN TRUST CORP | - | - | - | -44,476 | -100.00% | - | Mar 31, 2024 |
CITADEL ADVISORS LLC | - | - | - | -16,719 | -100.00% | - | Mar 31, 2024 |
As of Mar 31 2024, SAB Biotherapeutics's biggest institutional seller is BVF INC/IL. The company sold -9.18M shares of SABS, valued at -.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
BVF INC/IL | - | - | - | -9,178,282 | -100.00% | - | Mar 31, 2024 |
RTW INVESTMENTS, LP | - | - | - | -9,178,282 | -100.00% | - | Mar 31, 2024 |
SESSA CAPITAL IM, L.P. | - | - | - | -4,584,571 | -100.00% | - | Mar 31, 2024 |
VANGUARD GROUP INC | - | - | - | -996,132 | -100.00% | - | Mar 31, 2024 |
FIRST PREMIER BANK | - | - | - | -807,535 | -100.00% | - | Mar 31, 2024 |
PATHSTONE HOLDINGS, LLC | - | - | - | -506,513 | -100.00% | - | Mar 31, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -356,364 | -100.00% | - | Mar 31, 2024 |
FIRST MANHATTAN CO. LLC. | - | - | - | -277,777 | -100.00% | - | Mar 31, 2024 |
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | - | - | - | -192,027 | -100.00% | - | Mar 31, 2024 |
KESTRA ADVISORY SERVICES, LLC | - | - | - | -88,000 | -100.00% | - | Mar 31, 2024 |
STATE STREET CORP | - | - | - | -81,241 | -100.00% | - | Mar 31, 2024 |
MARINER, LLC | - | - | - | -69,000 | -100.00% | - | Mar 31, 2024 |
RENAISSANCE TECHNOLOGIES LLC | - | - | - | -63,100 | -100.00% | - | Mar 31, 2024 |
BLACKROCK INC. | - | - | - | -52,643 | -100.00% | - | Mar 31, 2024 |
PEAPACK GLADSTONE FINANCIAL CORP | - | - | - | -52,296 | -100.00% | - | Mar 31, 2024 |
SILVER OAK SECURITIES, INCORPORATED | - | - | - | -51,891 | -100.00% | - | Mar 31, 2024 |
CREATIVE PLANNING | - | - | - | -47,518 | -100.00% | - | Mar 31, 2024 |
ADVISOR GROUP HOLDINGS, INC. | - | - | - | -46,373 | -100.00% | - | Mar 31, 2024 |
NORTHERN TRUST CORP | - | - | - | -44,476 | -100.00% | - | Mar 31, 2024 |
CITADEL ADVISORS LLC | - | - | - | -16,719 | -100.00% | - | Mar 31, 2024 |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | - | - | - | -16,238 | -100.00% | - | Mar 31, 2024 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -15,235 | -100.00% | - | Mar 31, 2024 |
NADLER FINANCIAL GROUP, INC. | - | - | - | -13,750 | -100.00% | - | Mar 31, 2024 |
MORGAN STANLEY | - | - | - | -11,506 | -100.00% | - | Mar 31, 2024 |
1ST SOURCE BANK | - | - | - | -10,000 | -100.00% | - | Mar 31, 2024 |
BAIRD FINANCIAL GROUP, INC. | - | - | - | -10,000 | -100.00% | - | Mar 31, 2024 |
ELGETHUN CAPITAL MANAGEMENT | - | - | - | -5,435 | -100.00% | - | Mar 31, 2024 |
SPECTRUM WEALTH COUNSEL, LLC | - | - | - | -5,030 | -100.00% | - | Mar 31, 2024 |
LM ADVISORS LLC | - | - | - | -3,620 | -100.00% | - | Mar 31, 2024 |
GS INVESTMENTS, INC. | - | - | - | -2,000 | -100.00% | - | Mar 31, 2024 |
JPMORGAN CHASE & CO | - | - | - | -951 | -100.00% | - | Mar 31, 2024 |
UBS GROUP AG | - | - | - | -500 | -100.00% | - | Mar 31, 2024 |
FMR LLC | - | - | - | -343 | -100.00% | - | Mar 31, 2024 |
WELLS FARGO & COMPANY/MN | - | - | - | -294 | -100.00% | - | Mar 31, 2024 |
NEWEDGE ADVISORS, LLC | - | - | - | -145 | -100.00% | - | Mar 31, 2024 |
QUBE RESEARCH & TECHNOLOGIES LTD | - | - | - | -69 | -100.00% | - | Mar 31, 2024 |
BANK OF AMERICA CORP /DE/ | - | - | - | -54 | -100.00% | - | Mar 31, 2024 |
SAB Biotherapeutics's largest sold out institutional shareholder by shares sold is BVF INC/IL, sold -9.18M shares, valued at -, as of undefined.
SAB Biotherapeutics Mutual Fund Holders
Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
---|---|---|---|---|---|
BRIDGEWAY FUNDS INC | 0.04% | 84,000 | - | - | Mar 28, 2024 |
ALPS ETF Trust | 0.00% | 42,491 | - | - | Feb 29, 2024 |
VANGUARD INDEX FUNDS | 0.00% | 1,349,462 | - | - | Mar 31, 2024 |
ETF Managers Trust | 0.00% | 13,581 | - | - | Dec 31, 2023 |
FIDELITY CONCORD STREET TRUST | 0.00% | 328,656 | - | - | Feb 29, 2024 |
VANGUARD INDEX FUNDS | 0.00% | 174,128 | 174,128 | - | Mar 31, 2024 |
SCHWAB CAPITAL TRUST | 0.00% | 16,238 | - | - | Feb 29, 2024 |
VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 10,730 | - | - | Mar 31, 2024 |
ETF Series Solutions | 0.00% | 6,405 | - | - | Jan 31, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 33,159 | 33,159 | - | Feb 29, 2024 |
VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 787 | - | - | Mar 31, 2024 |
SCHWAB CAPITAL TRUST | 0.00% | 1,623 | 1,623 | - | Jan 31, 2024 |
VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 1,073 | 1,073 | - | Mar 31, 2024 |
USAA MUTUAL FUNDS TRUST | 0.00% | 3,587 | - | - | Jan 31, 2024 |
PROSHARES TRUST | 0.00% | 3,619 | - | - | Feb 29, 2024 |
EQ ADVISORS TRUST | 0.00% | 4,054 | - | - | Mar 31, 2024 |
iSHARES TRUST | 0.00% | 53,316 | - | - | Mar 31, 2024 |
Invesco Exchange-Traded Fund Trust II | 0.00% | 803 | - | - | Jan 31, 2024 |
JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 607 | - | - | Mar 31, 2024 |
SAB Biotherapeutics's largest mutual fund holder by % of total assets is "BRIDGEWAY FUNDS INC", owning 84.00K shares, compromising 0.04% of its total assets.
SAB Biotherapeutics Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
31 Dec, 23 | 37 | 5.71% |
30 Sep, 23 | 35 | -7.89% |
30 Jun, 23 | 38 | 2.70% |
31 Mar, 23 | 37 | 2.78% |
31 Dec, 22 | 36 | 2.86% |
30 Sep, 22 | 35 | - |
30 Jun, 22 | 35 | 34.62% |
31 Mar, 22 | 26 | -23.53% |
31 Dec, 21 | 34 | 3300.00% |
30 Sep, 21 | 1 | - |
As of 31 Dec 23, 37 institutions are holding SAB Biotherapeutics's shares, representing an increase of 5.71% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
31 Dec, 23 | 26,785,910 | 591.27% |
30 Sep, 23 | 3,874,859 | -2.09% |
30 Jun, 23 | 3,957,703 | 2.29% |
31 Mar, 23 | 3,868,963 | -5.44% |
31 Dec, 22 | 4,091,459 | 23.76% |
30 Sep, 22 | 3,306,084 | 7.32% |
30 Jun, 22 | 3,080,450 | 72.25% |
31 Mar, 22 | 1,788,313 | -42.24% |
31 Dec, 21 | 3,096,337 | 5060.56% |
30 Sep, 21 | 60,000 | - |
SAB Biotherapeutics (SABS) has 26.79M shares outstanding as of 31 Dec 23, up 591.27% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
31 Dec, 23 | 5.11% | 8.65% |
30 Sep, 23 | 7.68% | 12.46% |
30 Jun, 23 | 7.85% | 13.32% |
31 Mar, 23 | 7.68% | 8.69% |
31 Dec, 22 | 9.40% | 15.92% |
30 Sep, 22 | 7.68% | 14.97% |
30 Jun, 22 | 7.16% | 41.64% |
31 Mar, 22 | 4.15% | 8.18% |
31 Dec, 21 | 7.12% | 37395.36% |
30 Sep, 21 | 0.14% | - |
As of 31 Dec 23, SAB Biotherapeutics is held by 5.11% institutional shareholders, representing a 8.65% growth compared to 30 Sep 23.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
31 Dec, 23 | 15 | 50.00% |
30 Sep, 23 | 10 | -16.67% |
30 Jun, 23 | 12 | 9.09% |
31 Mar, 23 | 11 | -35.29% |
31 Dec, 22 | 17 | 21.43% |
30 Sep, 22 | 14 | -33.33% |
30 Jun, 22 | 21 | 31.25% |
31 Mar, 22 | 16 | -52.94% |
31 Dec, 21 | 34 | 3300.00% |
30 Sep, 21 | 1 | - |
15 institutional shareholders have increased their position in SABS stock as of 31 Dec 23 compared to 10 in the previous quarter (a 50.00% increase).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
31 Dec, 23 | 3 | 50.00% |
30 Sep, 23 | 2 | -50.00% |
30 Jun, 23 | 4 | -42.86% |
31 Mar, 23 | 7 | -12.50% |
31 Dec, 22 | 8 | 33.33% |
30 Sep, 22 | 6 | -14.29% |
30 Jun, 22 | 7 | 16.67% |
31 Mar, 22 | 6 | - |
31 Dec, 21 | - | - |
30 Sep, 21 | - | - |
3 institutional shareholders have reduced their position in SABS stock as of 31 Dec 23 compared to 2 in the previous quarter (a 50.00% increase).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
31 Dec, 23 | 37 | 5.71% | 26,785,910 | 591.27% | 5.11% | 8.65% | 15 | 50.00% | 3 | 50.00% |
30 Sep, 23 | 35 | -7.89% | 3,874,859 | -2.09% | 7.68% | 12.46% | 10 | -16.67% | 2 | -50.00% |
30 Jun, 23 | 38 | 2.70% | 3,957,703 | 2.29% | 7.85% | 13.32% | 12 | 9.09% | 4 | -42.86% |
31 Mar, 23 | 37 | 2.78% | 3,868,963 | -5.44% | 7.68% | 8.69% | 11 | -35.29% | 7 | -12.50% |
31 Dec, 22 | 36 | 2.86% | 4,091,459 | 23.76% | 9.40% | 15.92% | 17 | 21.43% | 8 | 33.33% |
30 Sep, 22 | 35 | - | 3,306,084 | 7.32% | 7.68% | 14.97% | 14 | -33.33% | 6 | -14.29% |
30 Jun, 22 | 35 | 34.62% | 3,080,450 | 72.25% | 7.16% | 41.64% | 21 | 31.25% | 7 | 16.67% |
31 Mar, 22 | 26 | -23.53% | 1,788,313 | -42.24% | 4.15% | 8.18% | 16 | -52.94% | 6 | - |
31 Dec, 21 | 34 | 3300.00% | 3,096,337 | 5060.56% | 7.12% | 37395.36% | 34 | 3300.00% | - | - |
30 Sep, 21 | 1 | - | 60,000 | - | 0.14% | - | 1 | - | - | - |
SAB Biotherapeutics Insider Shareholders Trades
Open Market Insider Trades
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
Open Market Insider Buys
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
Insider Sells
All Insider Owners Trades
The last insider sell of SAB Biotherapeutics's stock was made by Conley Mark William on Jun 24 2024, selling 25,000 shares at $4.79 per share (valued at $119.75K).
SAB Biotherapeutics Insider Ownership Trends
All Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q3 2024 | 18 | - | - |
Q2 2024 | - | 1 | - |
Q1 2024 | 5 | - | - |
Q4 2023 | 21 | 11 | 190.91% |
Q2 2023 | 1 | - | - |
Q1 2023 | 7 | 1 | 700.00% |
Q4 2022 | 6 | 1 | 600.00% |
Q3 2022 | 8 | - | - |
Q2 2022 | 3 | - | - |
Q1 2022 | 9 | - | - |
Q4 2021 | 101 | 6 | 1683.33% |
Q3 2021 | 3 | - | - |
Q1 2021 | 3 | 1 | 300.00% |
18 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by SAB Biotherapeutics's insiders, as of Q3 2024.
Open Market Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q3 2024 | - | - | - |
Q2 2024 | - | - | - |
Q1 2024 | - | - | - |
Q4 2023 | 3 | - | - |
Q2 2023 | - | - | - |
Q1 2023 | - | - | - |
Q4 2022 | - | - | - |
Q3 2022 | 2 | - | - |
Q2 2022 | - | - | - |
Q1 2022 | - | - | - |
Q4 2021 | 4 | 1 | 400.00% |
Q3 2021 | - | - | - |
Q1 2021 | 3 | - | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of SAB Biotherapeutics's stocks.
SAB Biotherapeutics Peer Ownership
Ticker | Company |
---|---|
FRTX | Fresh Tracks Therapeutics, Inc. |
MNPR | Monopar Therapeutics Inc. |
CVKD | Cadrenal Therapeutics, Inc. Common Stock |
PXMD | PaxMedica, Inc. Common Stock |
QNRX | Quoin Pharmaceuticals, Ltd. |
VRAX | Virax Biolabs Group Limited |
PCSA | Processa Pharmaceuticals, Inc. |
THRD | Third Harmonic Bio, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
UNCY | Unicycive Therapeutics, Inc. |
CDIO | Cardio Diagnostics Holdings, Inc. |
SABS Ownership FAQ
Who Owns SAB Biotherapeutics?
SAB Biotherapeutics is owned by institutional shareholders (5.11%), insiders (19.15%), and public (75.74%). The largest institutional shareholder of SAB Biotherapeutics is JPMORGAN CHASE & CO (0% of total shares) and the top mutual fund owner is BRIDGEWAY FUNDS INC (0.04% of total shares).
Who are the major institutional shareholders of SAB Biotherapeutics?
SAB Biotherapeutics's major institutional shareholders are JPMORGAN CHASE & CO, BANK OF AMERICA CORP /DE/, WELLS FARGO & COMPANY/MN, NORTHERN TRUST CORP, and STATE STREET CORP. The top five shareholders own together 0% of the company's share outstanding.
How many SAB Biotherapeutics shareholders are there?
As of Dec 2023, there are 37 institutional shareholders of SAB Biotherapeutics.
What percentage of SAB Biotherapeutics is owned by JPMORGAN CHASE & CO?
JPMORGAN CHASE & CO owns 0 shares of SAB Biotherapeutics, representing 0% of the company's total shares outstanding, valued at $0 (as of Mar 2024).
What percentage of SAB Biotherapeutics is owned by BANK OF AMERICA CORP /DE/?
As of Mar 2024, BANK OF AMERICA CORP /DE/ holds 0 shares of SAB Biotherapeutics (SABS), compromising 0% of the company, valued at $0.
What percentage of SAB Biotherapeutics is owned by WELLS FARGO & COMPANY/MN?
WELLS FARGO & COMPANY/MN is the third largest holder of SAB Biotherapeutics. The company owns 0 of the company's shares outstanding (worth $0).